SITE003-0154

SITE003 (CAN) › SITE003-0154

SITE003-0154

A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE003 (CAN) · Dr. Okafor
consented 2026-03-09

enrolled

AEs

2

Serious

0

Dropout signal

–

Adverse events

2

Grade 1 Nausea — outcome: RECOVERED/RESOLVED; onset 2023-01-20 (study day 131); relationship: not assessed

mild assessed

Grade 1 Pruritus — outcome: RECOVERED/RESOLVED; onset 2022-11-07 (study day 57); relationship: RELATED

mild assessed

Data queries

0

No data queries. Open queries would appear here for this patient.